Fig. 8From: Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibitionCrenigacestat inhibits the NOTCH1 pathway in iCCA hCAFs. Panel A. Crenigacestat inhibits the intracellular domain of Notch1 (NICD1) in a dose-dependent manner. Panel B and C. HES1, at both mRNA and protein expression, is downregulated in iCCA hCAFs at all the concentrations used of Crenigacestat. *p < 0.05, **p < 0.01, ***p < 0.001 calculated with Student’s t-testBack to article page